Sinopsys Surgical gains $8.3M funding round for sinusitis device | Medtech funding for the week of October 20, 2014

Sinopsys Surgical sniffs up $8.3m for sinusitis device

October 17, 2014 by Alexander Soule

Stealth-mode startup Sinopsys Surgical said it raised $8.3 million in an equity funding round for the technique it’s developing to repurpose the tear duct to drain into the sinuses as a way to relieve chronic sinusitis.

CEO Dr. Harry Ross was a partner with Aweida Venture Partners of Superior, Colo., near to Sinopsys Surgical’s Boulder headquarters. Read more

ZipLine Medical adds $5.7m to Series C round

October 20, 2014 by Alexander Soule

ZipLine Medical said it added a $5.7 million extension to its $4.3 million Series C round, with new investor China Materialia promising to help the company expand sales in the People’s Republic.

“This Series C extension allows us to further expand our sales and marketing activities to leverage the overwhelming support we are receiving from key opinion leaders among clinicians,” ZipLine CEO John Tighe said in prepared remarks. Read more

Medrobotics taps backers for $20m

October 21, 2014 by Alexander Soule

Medrobotics said it closed on $20 million in new funding in a preferred stock sale to prior backers as plans to expand its commercial footprint in Europe.

Raynham, Mass.-based Medrobotics also said that it’s “met all applicable FDA requirements” to distribute its Flex Retractor in the U.S. Read more

Sensory Medical raises $1.4m for Relaxis restless legs treatment

October 21, 2014 by Alexander Soule

Sensory Medical shook a leg on a 2nd tranche of funding since receiving FDA clearance last spring for its device to relieve symptoms of restless legs syndrome, reporting $1.4 million in fresh funding on the heels of a $1 million tranche in June.

Restless leg syndrome is a neurological disorder that causes sensations giving people the urge to move and reposition their legs to relieve discomfort, disrupting their sleep. Scientists have yet to pin down the cause of RLS, but some suspect it is genetic in origin. Read more

Stealth hypertension startup Sympara Medical raises nearly $6m

October 23, 2014 by Alexander Soule

Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it’s developing.

San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million with the SEC in 2013. Read more